 |
Palleon Pharmaceuticals
CEO Jim Broderick
USA | Funding: $147.6M (+)
Website: http://palleonpharma.com/
Palleon Pharmaceuticals develops drugs that target sugar-sensing molecules on the surfaces of cells. It has integrated technologies and insights from world-renowned scientific leaders in glycoscience and human immunology to create the first Glycoimmune Checkpoint Inhibitors to treat cancer patients.
Website: http://palleonpharma.com/
Palleon Pharmaceuticals develops drugs that target sugar-sensing molecules on the surfaces of cells. It has integrated technologies and insights from world-renowned scientific leaders in glycoscience and human immunology to create the first Glycoimmune Checkpoint Inhibitors to treat cancer patients.
